Ready to get certified?

Free CDCES Coach App

Subscribe

eNewsletter

Diabetes Education Services 25 years anniversary logo

Download

Free Med Pocket Cards

New SGLT-2 Inhibitor – Ertugliflozin

New SGLT-2 Inhibitor – Ertugliflozin

The Food and Drug Administration (FDA) has approved Ertugliflozin (Steglatro), a new SGLT-2 Inhibitor to treat adults with type 2 diabetes. Also approved are two new combination medications with ertugliflozin.  These include Segluromet (ertugliflozin plus metformin) and Steglujan (ertugliflozin plus sitagliptin). See box below for available combination doses (in mgs).

Dosing range: 5 -15 mg daily.  Monitor GFR before starting. Don’t start med if GFR is less than 60 and stop if GFR is less than 30.

Considerations: Ertugliflozin has the same warnings as other SGLT-2s: Watch for hypotension, UTI’s, increased urination, genital infections, ketoacidosis.

Benefits: no hypoglyecmia or weight gain.
Lowers A1c 1.0% – 2.0%. Lowers wt 1-3 lbs.

Download our FREE Updated Insulin PocketCard

Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.

If you want cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice, we highly recommend this Meds Update.

To Join Us and earn CEs you have 2 options: 

Sign up for Diabetes Blog Bytes!

We post weekly Blog Bytes that are informative and FREE! Every week we post one exam practice Question of the Week and Rationale of the Week. Sign up below!

Form Heading

Newly Expanded Accreditation!​

For more information on accreditation, visit each individual course page in our Online Store and click the “Accreditation” tab

Our course CE credits are through the following accrediting bodies:

  • AMA PRA Category 1 Credits™,
  • ACPE,
  • ANCC, and
  • CDR

Course credits will continue to count toward the CDCES and BC-ADM certification requirements, and many of our offerings (all of Standards of Care Intensive courses, plus our Virtual and Live DiabetesEd Training Conferences) fulfill the ADA Standards of Care component required for certification renewal.

The use of DES products does not guarantee the successful passage of the certification exam. CBDCE and ADCES do not endorse any preparatory or review materials for the CDCES or BC-ADM exams, except for those published by CBDCE & ADCES.

Recent Blog Bytes

Footer Left Description

Diabetes Education Services offers education and training to diabetes educators in the areas of both Type 1 and Type 2 Diabetes for the novice to the established professional. Whether you are training to be a Certified Diabetes Care and Education Specialist (CDCES), practicing at an advanced level and interested in board certification, or a health care professional and/or Certified Diabetes Care and Education Specialist (CDCES) who needs continuing education hours to renew your license or CDCES, we have diabetes education information, resources and training; learning and teaching tools; and diabetes online courses available for continuing education (CE). Read our disclaimer for full disclosure.

Social Links

Sign up for our

 

Follow Us on

 

  • © 2025 Diabetes Education Services, All Rights Reserved. Privacy Policy
    530-893-8635